Table Info

Table 3.

Assessment of the feasibility of non-plasma type biological specimens/materials for minimally invasive liquid biopsy

References	Material	Method	The number of samples analyzed	Panel size (the number of genes)
Hubers et al. [47]	Sputum	ddPCR, NGS panel	10	1 (EGFR)
Morikawa et al. [48]	Sputum	NGS panel	3	8 genes
Roncarati et al. [49]	Bronchiral washing fluids	NGS panel	73	14 genes
Zhai et al. [50]	Bronchiral washing fluids	NGS panel	20	1,021 genes
Zhang et al. [51]	Bronchiral washing fluids	PCR (Alldetect™ EGFR Mutation Test Kit)	144	1 (EGFR)
Tu et al. [52]	Pleural effusion	NGS panel	32	448 genes

Declarations

Author contributions

The author contributed solely to the work.

Conflicts of interest

The author declares that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, et al. Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J Cancer. 2013;4:736–54. [DOI] [PubMed] [PMC]

Yang YP, Ma YX, Huang Y, Zhao YY, Fang WF, Hong SD, et al. QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Sci Rep. 2015;5:11934. [DOI] [PubMed] [PMC]

Chen G, Feng J, Zhou C, Wu YL, Liu XQ, Wang C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol. 2013;24:1615–22. [DOI] [PubMed]

Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, et al. Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial. J Mol Diagn. 2017;19:313–27. [DOI] [PubMed] [PMC]

Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, et al. Clinical and analytical validation of FoundationOne^®CDx, a comprehensive genomic profiling assay for solid tumors. PLoS One. 2022;17:e0264138. [DOI] [PubMed] [PMC]

Benlloch S, Botero ML, Beltran-Alamillo J, Mayo C, Gimenez-Capitán A, de Aguirre I, et al. Clinical validation of a PCR assay for the detection of EGFR mutations in non–small-cell lung cancer: retrospective testing of specimens from the EURTAC trial. PLoS One. 2014;9:e89518. [DOI] [PubMed] [PMC]

Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One. 2015;10:e0140712. [DOI] [PubMed] [PMC]

Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One. 2020;15:e0237802. [DOI] [PubMed] [PMC]

10.

Bormann Chung C, Lee J, Barritault M, Bringuier PP, Xu Z, Huang WY, et al. Evaluating targeted next-generation sequencing assays and reference materials for NTRK fusion detection. J Mol Diagn. 2022;24:18–32. [DOI] [PubMed]

11.

Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A, Palmieri G. Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer. Int J Mol Sci. 2021;22:612. [DOI] [PubMed] [PMC]

12.

Calles A, Riess JW, Brahmer JR. Checkpoint blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ Book. 2020;40:372–84. [DOI] [PubMed]

13.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39. [DOI] [PubMed] [PMC]

14.

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35. [DOI] [PubMed] [PMC]

15.

Katayama Y, Shimamoto T, Yamada T, Takeda T, Yamada T, Shiotsu S, et al. Retrospective efficacy analysis of immune checkpoint inhibitor rechallenge in patients with non-small cell lung cancer. J Clin Med. 2019;9:E102. [DOI] [PubMed] [PMC]

16.

Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24:1441–8. [DOI] [PubMed]

17.

Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al.; ADAURA Investigators. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–23. [DOI] [PubMed]

18.

Taus Á, Camacho L, Rocha P, Hardy-Werbin M, Pijuan L, Piquer G, et al. Dynamics of EGFR mutation load in plasma for prediction of treatment response and disease progression in patients with EGFR-mutant lung adenocarcinoma. Clin Lung Cancer. 2018;19:387–94.e233. [DOI] [PubMed]

19.

Dziadziuszko R, Peters S, Mok T, Camidge DR, Gadgeel SM, Ou SI, et al. Circulating cell-free DNA as a prognostic biomarker in patients with advanced ALK+ non-small cell lung cancer in the global phase III ALEX trial. Clin Cancer Res. 2022;28:1800–8. [DOI] [PubMed]

20.

Knapp B, Mezquita L, Devarakonda S, Aldea M, Waqar SN, Pepin K, et al. Exploring the feasibility of utilizing limited gene panel circulating tumor DNA clearance as a biomarker in patients with locally advanced non-small cell lung cancer. Front Oncol. 2022;12:856132. [DOI] [PubMed] [PMC]

21.

Palmero R, Taus A, Viteri S, Majem M, Carcereny E, Garde-Noguera J, et al. Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer. JCO Precis Oncol. 2021;5:93–102. [DOI] [PubMed]

22.

Schouten RD, Vessies DCL, Bosch LJW, Barlo NP, van Lindert ASR, Cillessen SAGM, et al. Clinical utility of plasma-based comprehensive molecular profiling in advanced non-small-cell lung cancer. JCO Precis Oncol. 2021;5:PO.20.00450. [DOI] [PubMed] [PMC]

23.

Fiala O, Baxa J, Svaton M, Benesova L, Ptackova R, Halkova T, et al. Combination of circulating tumour DNA and 18F-FDG PET/CT for precision monitoring of therapy response in patients with advanced non-small cell lung cancer: a prospective study. Cancer Genomics Proteomics. 2022;19:270–81. [DOI] [PubMed] [PMC]

24.

Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, et al. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Med. 2021;10:2216–31. [DOI] [PubMed] [PMC]

25.

Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, et al. Plasma ctDNA response is an early marker of treatment effect in advanced NSCLC. JCO Precis Oncol. 2021;5:PO.20.00419. [DOI] [PubMed] [PMC]

26.

Kowanetz M, Zou W, Shames DS, Cummings C, Rizvi N, Spira A, et al. OA20.01 Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients. J Thorac Oncol. 2017;12:S321–2. [DOI]

27.

Ross JS, Goldberg ME, Albacker LA, Gay LM, Agarwala V, Elvin JA, et al. Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC). Ann Oncol. 2017;28:v404. [DOI]

28.

Singal G, Miller PG, Agarwala V, Li G, Gossai A, Albacker LA, et al. Analyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database. Ann Oncol. 2017;28:v404–5. [DOI]

29.

Kang SP, Gergich K, Lubiniecki GM, de Alwis DP, Chen C, Tice MAB, et al. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol. 2017;28:1388–98. [DOI] [PubMed] [PMC]

30.

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–104. [DOI] [PubMed] [PMC]

31.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al.; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–65. Erratum in: Lancet. 2017;389:e5. [DOI] [PubMed] [PMC]

32.

Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18. [DOI] [PubMed]

33.

Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22:1342–50. Erratum in: Nat Med. 2017;23:1241. Erratum in: Nat Med. 2018;24:525. [DOI] [PubMed]

34.

Yang G, Zheng RY, Jin ZS. Correlations between microsatellite instability and the biological behaviour of tumours. J Cancer Res Clin Oncol. 2019;145:2891–9. [DOI] [PubMed] [PMC]

35.

Yanagawa N, Yamada N, Sugimoto R, Osakabe M, Uesugi N, Shiono S, et al. The frequency of DNA mismatch repair deficiency is very low in surgically resected lung carcinoma. Front Oncol. 2021;11:752005. [DOI] [PubMed] [PMC]

36.

De Marchi P, Berardinelli GN, Cavagna RO, Pinto IA, da Silva FAF, Duval da Silva V, et al. Microsatellite instability is rare in the admixed brazilian population of non-small cell lung cancer: a cohort of 526 cases. Pathobiology. 2022;89:101–6. [DOI] [PubMed]

37.

Brown LC, Tucker MD, Sedhom R, Schwartz EB, Zhu J, Kao C, et al. LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. J Immunother Cancer. 2021;9:e001792. [DOI] [PubMed] [PMC]

38.

Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561–5. Erratum in: Nature. 2020;580:E1. [DOI] [PubMed]

39.

Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549–55. [DOI] [PubMed] [PMC]

40.

Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, et al. A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: results from the MYSTIC study. Clin Cancer Res. 2021;27:1631–40. [DOI] [PubMed]

41.

Wang Y, Tong Z, Zhang W, Zhang W, Buzdin A, Mu X, et al. FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients. Front Oncol. 2021;11:683419. [DOI] [PubMed] [PMC]

42.

Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell. 2020;183:363–76.e13. [DOI] [PubMed] [PMC]

43.

Weber S, van der Leest P, Donker HC, Schlange T, Timens W, Tamminga M, et al. Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. JCO Precis Oncol. 2021;5:1540–53. Erratum in: JCO Precis Oncol. 2022;6:e2100566. [DOI] [PubMed]

44.

Xiong A, Nie W, Zhou Y, Li C, Gu K, Zhang D, et al. Comutations in DDR pathways predict atezolizumab response in non-small cell lung cancer patients. Front Immunol. 2021;12:708558. [DOI] [PubMed] [PMC]

45.

Lu J, Zhang Y, Lou Y, Yan B, Zou B, Hu M, et al. ctDNA-profiling-based UBL biologicalprocess mutation status as a predictor of Atezolizumab response among TP53-negative NSCLC patients. Front Genet. 2021;12:723670. [DOI] [PubMed] [PMC]

46.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. [DOI] [PubMed] [PMC]

47.

Hubers AJ, Heideman DAM, Yatabe Y, Wood MD, Tull J, Tarón M, et al. EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study. Lung Cancer. 2013;82:38–43. [DOI] [PubMed]

48.

Morikawa K, Kinoshita K, Kida H, Inoue T, Mineshita M. Preliminary results of NGS gene panel test using NSCLC sputum cytology and therapeutic effect using corresponding molecular-targeted drugs. Genes (Basel). 2022;13:812. [DOI] [PubMed] [PMC]

49.

Roncarati R, Lupini L, Miotto E, Saccenti E, Mascetti S, Morandi L, et al. Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer. Mol Oncol. 2020;14:2163–75. [DOI] [PubMed] [PMC]

50.

Zhai J, Han S, Guo Q, Shan B, Wang J, Guo Y, et al. Identifying genomic alterations in small cell lung cancer using the liquid biopsy of bronchial washing fluid. Front Oncol. 2021;11:647216. [DOI] [PubMed] [PMC]

51.

Zhang X, Li C, Ye M, Hu Q, Hu J, Gong Z, et al. Bronchial washing fluid versus plasma and bronchoscopy biopsy samples for detecting epidermal growth factor receptor mutation status in lung cancer. Front Oncol. 2021;11:602402. [DOI] [PubMed] [PMC]

52.

Tu HY, Li YS, Bai XY, Sun YL, Zheng MY, Ke EE, et al. Genetic profiling of cell-free DNA from pleural effusion in advanced lung cancer as a surrogate for tumor tissue and revealed additional clinical actionable targets. Clin Lung Cancer. 2022;23:135–42. [DOI] [PubMed]

53.

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7:1394–403. [DOI] [PubMed] [PMC]

54.

Qiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y, et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021;12:6770. [DOI] [PubMed] [PMC]

55.

Gale D, Heider K, Ruiz-Valdepenas A, Hackinger S, Perry M, Marsico G, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol. 2022;33:500–10. [DOI] [PubMed] [PMC]